Clinical trials: Cardiac Bypass Patients
Pulmonary Hypertension
VentaProst Versus Conventionally-Administered Aerosolized Epoprostenol in Patients Undergoing Cardiac Surgery With CPB
The purpose of the Phase 2a study is to: 1) demonstrate that the estimated VentaProst dose is safe and equivalent in effect to a dose administered via epoprostenol aerosolization by the current off-label-use practice; and 2)…
- Trial name
- NCT03122730
- Testing
- VentaProst
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Aerogen Pharma Limited
Ischemic Heart Disease
Safety Study of Gene Therapy for Ischemic Heart Disease in Korea
The purpose of this study is to evaluate the safety of VM202 (Engensis) direct injection into the cardiac muscles of the coronary artery territory where complete revascularization could not be done even through Coronary Artery…
- Trial name
- Engensis (NCT01422772)
- Testing
- VM202-0.5 mg, VM202-1.0 mg, VM202-2.0 mg
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Helixmith Co., Ltd.
Congestive Heart Failure
Feasibility Study of BMAC Enhanced CABG
Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium
- Trial name
- NCT01074099
- Testing
- BMAC, CABG only
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- Harvest Technologies
CABG
Effect of GLP - 1 (7-36 Amide) on Myocardial Function Following Coronary Artery Bypass (CABG) Surgery
This research is being done to see if giving a hormone called GLP-1 can improve heart function and reduce length of stay in the Cardiac Surgical Intensive Care Unit (CSICU) in people who have non-emergent coronary artery bypass…
- Trial name
- GLP-1 CABG (NCT00966654)
- Testing
- GLP-1 (7-36) amide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Johns Hopkins University
Disorder of Vitamin C, Atrial Fibrillation
High Dose Vitamin C in Cardiac Surgery Patients
Coronary artery bypass grafting (CABG) is the most common procedure performed by cardiac surgeons. Post-operative atrial fibrillation (AF) is the most common adverse event following CABG, experienced in 20-50% of patients; the…
- Conditions
- Disorder of Vitamin C, Atrial Fibrillation, Complications Due to Coronary Artery Bypass Graft, Heart Valve Disease
- Trial name
- NCT02762331
- Testing
- Ascorbic Acid
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Virginia Commonwealth University
Myocardial Ischemia, Acute Coronary Syndrome
Cardiac Rehabilitation for Heart Event Recovery (HER)
The purpose of this study is to compare women's cardiac rehabilitation program adherence across three program models.
- Conditions
- Myocardial Ischemia, Acute Coronary Syndrome, Heart Disease, Coronary Artery Disease
- Trial name
- CR4HER (NCT01019135)
- Testing
- Cardiac Rehabilitation
- Where
- 5 sites in Canada
- Volunteers
- 169 people
- Sponsor
- University Health Network, Toronto
Opioid Use, Unspecified
Methadone vs. Fentanyl Administration on Postoperative Pain Control in Pediatric Patients Undergoing Cardiac Surgery
The purpose of this study is to determine if methadone improves postoperative pain control in pediatric patient's undergoing cardiac surgery.
- Trial name
- CV_RCT_M_F (NCT02747875)
- Testing
- Methadone, Fentanyl
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Andrew Waberski
Coronary Artery Disease
Transepicardial With Transseptal Autologous CD 133+ Bone Marrow Cell Implantation in Patient Following CABG Surgery
Heart Failure has several etiologies and one of them is coronary artery disease. Coronary artery bypass grafting (CABG) is one of revascularizations method which has been used for decades in coronary artery disease theraphy.
- Trial name
- NCT02870933
- Testing
- Transepicardial with Transseptal CD 133+ Implantation
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- National Cardiovascular Center Harapan Kita Hospital Indonesia
Prevention & Control
Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease
The primary objectives of this study are: To determine whether rivaroxaban 2.5 mg twice daily (bid) + aspirin 100 mg once daily (od) compared with aspirin 100 mg od reduces the risk of a composite of myocardial infarction…
- Trial name
- COMPASS (NCT01776424)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Pantoprazole
- Where
- 565 sites in United States, Argentina and 31 more
- Volunteers
- 27,395 people
- Sponsor
- Bayer
Surgery, Coronary Artery Disease
Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery
The purpose of this study is to examine whether the use of Sugammadex will reduce time from reversal to extubation and improve other post extubation outcomes in Coronary artery bypass grafting patients.
- Trial name
- NCT03939923
- Testing
- Rocuronium, Neostigmine, Glycopyrrolate
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- West Virginia University
Cardiac Surgery, Cardiopulmonary Bypass
Voluven® in Paediatric Patients
This study will compare the clinical efficacy and safety of Voluven® and Human Albumin during elective open-heart surgery in pediatric patients.
- Trial name
- NCT00860405
- Testing
- HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L), Human serum albumin (HSA 50g/L)
- Where
- 2 sites in Austria, Belgium
- Volunteers
- 61 people
- Sponsor
- Fresenius Kabi
Stem Cell Transplantation, Ventricular Dysfunction, Left
Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)
Heart attacks are a leading cause of death in both men and women in the United States. When a person has a heart attack, blood is unable to reach a certain area of the heart, and if the blood supply is not re-established quickly…
- Trial name
- PROMETHEUS (NCT00587990)
- Testing
- Lower dose mesenchymal stem cell (MSC) injection, Higher dose MSC injection
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Joshua M Hare
Coronary Artery Diseases, Multivessel Coronary Artery Disease
SYNTAX III REVOLUTION Trial: A Randomized Study Investigating the Use of CT Scan and Angiography of the Heart to Help the Doctors Decide Which Method is the Best to Improve Blood Supply to the Heart in Patients With Complex Coronary Artery Disease
The SYNTAX III Revolution trial is a randomized diagnostic research study that investigates the use of CT scan and angiogram of the heart to help doctors decide which method is the best to improve blood supply to the heart in…
- Conditions
- Coronary Artery Diseases, Multivessel Coronary Artery Disease, Heart Diseases, Cardiovascular Diseases
- Trial name
- SYNTAX III (NCT02813473)
- Testing
- Coronary Angiography, Computed Tomography (CT) scan
- Where
- 6 sites in Belgium, France and 3 more
- Volunteers
- 223 people
- Sponsor
- ECRI bv
Acute Kidney Injury
Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.
The purpose of this study is to determine whether nitric oxide is effective in the treatment of acute kidney injury in cardiac surgical patients with sign and laboratory data suggesting endothelial dysfunction undergoing…
- Trial name
- MGHK23 (NCT02836899)
- Testing
- Nitric Oxide
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Massachusetts General Hospital
Acute Kidney Injury
Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI
Acute kidney injury (AKI) occurs in up to 30% of patients undergoing coronary artery bypass graft (CABG) surgery, and often requires patients to go on dialysis.
- Trial name
- NCT03810417
- Testing
- Digoxin Antibodies Fab Fragments, Baseline EO > 360 pM, EO < 360 pM
- Where
- 2 sites in United States
- Volunteers
- 267 people
- Sponsor
- University of Maryland, Baltimore
Hyperglycemia
Sitagliptin for Hyperglycemia in Patients With T2DM Undergoing Cardiac Surgery
The purpose of this study is to determine whether treatment with sitagliptin reduces the frequency and severity of high blood sugar (hyperglycemia) after cardiac surgery and to determine whether treatment with sitagliptin is…
- Trial name
- SITA-CABGDM (NCT02556918)
- Testing
- Sitagliptin, Regular Human Insulin, Insulin glargine
- Where
- 3 sites in United States
- Volunteers
- 202 people
- Sponsor
- Emory University
Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
Sugammadex and Decreased Time to Extubation
The purpose of this study is to demonstrate faster time to extubation after arrival in the cardiothoracic intensive care unit (ICU) in patients undergoing isolated coronary artery bypass grafting (CABG), AVR and AVR/CABG…
- Trial name
- NCT03196167
- Testing
- Sugammadex
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Yale University
Arteriosclerosis of Coronary Artery Bypass Graft
Graft Patency Outcomes in Patients Undergoing Coronary Artery Bypass Grafting Via Minimally Invasive Coronary Surgery
This clinical study has been developed to evaluate the clinical outcomes in patients undergoing coronary artery bypass grafting via Minimally Invasive Coronary Surgery (MICS); a minimally invasive coronary bypass procedure that…
- Trial name
- MICS (NCT01334866)
- Testing
- Minimally invasive coronary artery bypass graft surgery
- Where
- 2 sites in United States, Canada
- Volunteers
- 91 people
- Sponsor
- Medtronic Cardiovascular
Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Multi-national Study Investigating the Effect and Safety of rFXIII on Transfusion Needs in Patients Undergoing Heart Surgery
This trial is conducted in Canada, Asia, Europe and USA. The aim of this clinical trial is to investigate the effect and safety of rFXIII on transfusion needs in patients undergoing heart surgery.
- Trial name
- NCT00914589
- Testing
- catridecacog
- Where
- 32 sites in United States, Canada and 8 more
- Volunteers
- 479 people
- Sponsor
- Novo Nordisk A/S
Chronic Kidney Disease, CKD
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
The primary objective of this study is to assess the efficacy of a single dose of ravulizumab IV compared with placebo in reducing the risk of the clinical consequences of AKI (MAKE) at 90 days in adult participants with CKD who…
- Conditions
- Chronic Kidney Disease, CKD, Cardiac Disease, Cardiopulmonary Bypass
- Trial name
- ARTEMIS (NCT05746559)
- Testing
- Ravulizumab
- Where
- 130 sites in United States, Argentina and 18 more
- Volunteers
- 555 people
- Sponsor
- Alexion Pharmaceuticals, Inc.